Key Insights

Highlights

Success Rate

85% trial completion

Published Results

295 trials with published results (27%)

Research Maturity

741 completed trials (67% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

12.2%

135 terminated out of 1111 trials

Success Rate

84.6%

-1.9% vs benchmark

Late-Stage Pipeline

18%

195 trials in Phase 3/4

Results Transparency

40%

295 of 741 completed with results

Key Signals

295 with results85% success135 terminated

Data Visualizations

Phase Distribution

927Total
Not Applicable (215)
Early P 1 (10)
P 1 (228)
P 2 (279)
P 3 (132)
P 4 (63)

Trial Status

Completed741
Terminated135
Unknown109
Recruiting57
Withdrawn28
Active Not Recruiting19

Trial Success Rate

84.6%

Benchmark: 86.5%

Based on 741 completed trials

Clinical Trials (1111)

Showing 20 of 20 trials
NCT06584357Recruiting

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

NCT06976216Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT07170150Phase 3RecruitingPrimary

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT03672201Not ApplicableActive Not RecruitingPrimary

Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia

NCT07346794Not ApplicableNot Yet RecruitingPrimary

The Underlying Neural Mechanism of TMS in Improving the Imbalance of "Microbiota-brain-gut Axis" in Alzheimer 's Disease Population

NCT01638949Not ApplicableCompletedPrimary

Multi-modal Neuroimaging in Alzheimer's Disease IMAP+

NCT06976203Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT07214727Phase 1RecruitingPrimary

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

NCT05655195Not ApplicableRecruiting

Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy

NCT03140865RecruitingPrimary

Wake Forest Alzheimer's Disease Clinical Core

NCT02941289Not ApplicableCompletedPrimary

Visuospatial Attention, Eye Movements and Instrumental Activities of Daily Living (IADLs) in Alzheimer's Disease

NCT07094516Phase 2RecruitingPrimary

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

NCT05020106RecruitingPrimary

The Diagnostic Cut-off Value of Core Biomarkers of Alzheimer's Disease

NCT04850053RecruitingPrimary

Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis

NCT07485153Not Yet RecruitingPrimary

A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's Disease

NCT07479914Not ApplicableActive Not Recruiting

Art of Memory for Cognitive Enhancement in the Monza Brain Health Service

NCT04639050Phase 1Active Not RecruitingPrimary

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

NCT07457138Recruiting

Lombard Cohort of Brain Health Services

NCT07250113Not ApplicableEnrolling By Invitation

WeCareToFeedDysphagia to Reduce Care-partner Burden Full-scale RCT

NCT00647478CompletedPrimary

System-IGF-1 Pathway and Alzheimer's Disease

Scroll to load more

Research Network

Activity Timeline